Supported by phase 3 SYMPHONY and ENCORE trial data, AXS-12 significantly reduced weekly cataplexy attacks and improved daytime sleepiness and cognition.

Axsome Therapeutics (AXSM) stock gains as the FDA accepts the company's marketing application for its narcolepsy therapy ...

When it comes to feeling better, most of us think of doctor visits, prescriptions, or tried-and-tested advice. But every now ...

Xander Furlong, 18, died from natural causes while on a sea turtle conservation project in Costa Rica ...

Drug companies have already bypassed Australia as a market for some of the world’s most innovative medicines, including the ...